Carfilzomib: A second-generation proteasome inhibitor for the treatment of multiple myeloma

American Journal of Health-System Pharmacy

Volumn 72, Issue 5, 2015, Pages 353-360

  McBride, Ali ^a   Klaus, Jeff O ^b   Stockerl Goldstein, Keith ^c  

^a UNIVERSITY OF ARIZONA   (United States)

^b BARNES JEWISH HOSPITAL   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CARFILZOMIB; LENALIDOMIDE; THALIDOMIDE; ANTINEOPLASTIC AGENT; OLIGOPEPTIDE; PROTEASOME INHIBITOR;

ANEMIA; BODY SURFACE; CANCER SURVIVAL; COUGHING; DISEASE EXACERBATION; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DYSPNEA; FATIGUE; HEART ARREST; HEART FAILURE; HUMAN; HYPERTENSION; IMMUNOMODULATION; INFUSION RELATED REACTION; KIDNEY DYSFUNCTION; LIVER FAILURE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE MYELOMA; NAUSEA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; CLINICAL TRIAL (TOPIC);

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG COSTS; HUMANS; MULTIPLE MYELOMA; OLIGOPEPTIDES; PROTEASOME INHIBITORS;

EID: 84933514049     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp130281     Document Type: Review

References (50)

1. Siegel R, Ward E, Brawley O et al. Cancer statistics, 2011. CA Cancer J Clin. 2011; 61:212-36.
2. Anderson KC, Alsina M, Bensinger W et al. Multiple myeloma. J Natl Compr Canc Netw. 2011; 9:1146-83.
3. Howlader N, Noone NA, Krapcho M et al., eds. SEER cancer statistics review, 1975-2008. Bethesda, MD: National Cancer Institute; 2011.
4. Perrotta C, Staines A. Multiple myeloma and occupation. A systematic review of the literature. Ir J Med Sci. 2006; 175:1-29.
5. Perrotta C, Staines A, Cocco P. Multiple myeloma and farming. A systematic review of 30 years of research. Where next? J Occup Med Toxicol. 2008; 3:27.
6. Perrotta C, Staines A, Codd M et al. Multiple myeloma and lifetime occupation: results from the EPILYMPH study. J Occup Med Toxicol. 2012; 7:25.
7. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011; 364:1046-60.
8. Attal M, Harousseau JL, Facon T et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003; 349:2495-502.
9. Giralt S. Stem cell transplantation for multiple myeloma: current and future status. Hematol Am Soc Hematol Educ Program. 2011; 2011:191-6.
10. Anderson KC. Targeted therapy of multiple myeloma based upon tumormicroenvironmental interactions. Exp Hematol. 2007; 35:155-62.
11. Bianchi G, Ghobrial IM. Molecular mechanisms of effectiveness of novel therapies in multiple myeloma. Leuk Lymphoma. 2013; 54:229-41.
12. McBride A, Ryan PY. Proteasome inhibitors in the treatment of multiple myeloma. Expert Rev Anticancer Ther. 2013; 13:339-58.
13. Andhavarapu S, Roy V. Immunomodulatory drugs in multiple myeloma. Expert Rev Hematol. 2013; 6:69-82.
14. Kumar SK, Lee JH, Lahuerta JJ et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter International Myeloma Working Group study. Leukemia. 2012; 26:149-57.
15. Lawasut P, Chauhan D, Laubach J et al. New proteasome inhibitors in myeloma. Curr Hematol Malig Rep. 2012; 7:258-66.
16. Lonial S, Mitsiades CS, Richardson PG. Treatment options for relapsed and refractory multiple myeloma. Clin Cancer Res. 2011; 17:1264-77.
17. Markovina S, Callander NS, O'Connor SL et al. Bortezomib-resistant nuclear factor-kB activity in multiple myeloma cells. Mol Cancer Res. 2008; 6:1356-64.
18. Oerlemans R, Franke NE, Assaraf YG et al. Molecular basis of bortezomib resistance: proteasome subunit β5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood. 2008; 112:2489-99.
19. Kuhn DJ, Chen Q, Voorhees PM et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitinproteasome pathway, against preclinical models of multiple myeloma. Blood. 2007; 110:3281-90.
20. Arastu-Kapur S, Anderl JL, Kraus M et al. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res. 2011; 17:2734-43.
21. Hideshima T, Anderson KC. Biologic impact of proteasome inhibition in multiple myeloma cells-from the aspects of preclinical studies. Semin Hematol. 2012; 49:223-7.
22. Adams J. The proteasome: structure, function, and role in the cell. Cancer Treat Rev. 2003; 29:3-9.
23. Kuhn DJ, Orlowski RZ. The immunoproteasome as a target in hematologic malignancies. Semin Hematol. 2012; 49:258-62.
24. Khan ML, Stewart AK. Carfilzomib: a novel second-generation proteasome inhibitor. Future Oncol. 2011; 7:607-12.
25. Wang Z, Yang J, Kirk C et al. Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib. Drug Metab Dispos. 2013; 41:230-7.
26. Yang J, Wang Z, Fang Y et al. Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats. Drug Metab Dispos. 2011; 39:1873-82.
27. Badros AZ, Vij R, Martin T et al. Phase II study of carfilzomib in patients with relapsed/refractory multiple myeloma and renal insufficiency. J Clin Oncol. 2010; 28(suppl):15s.
28. Demo SD, Kirk CJ, Aujay MA et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 2007; 67:6383-91.
29. Nooka A, Gleason C, Casbourne D, Lonial S. Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib. Biologics. 2013; 7:13-32.
30. O'Connor OA, Stewart AK, Vallone M et al. A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res. 2009; 15:7085-91.
31. Alsina M, Trudel S, Furman RR et al. A phase I single-agent study of twiceweekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clin Cancer Res. 2012; 18:4830-40.
32. Jagannath S, Vij R, Stewart AK et al. An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, singleagent carfilzomib in patients with relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2012; 12:310-8.
33. Siegel DS, Martin T, Wang M et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012; 120:2817-25.
34. Vij R, Wang M, Kaufman JL et al. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood. 2012; 119:5661-70.
35. Fostier K, De Becker A, Schots R. Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma. Onco Targets Ther. 2012; 5:237-44.
36. Hajek R, Bryce R, Ro S et al. Design and rationale of FOCUS (PX-171-011): a randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM). BMC Cancer. 2012; 12:415.
37. ClinicalTrials.gov. Phase 3 study with carfilzomib and dexamethasone versus velcade and dexamethasone for relapsed multiple myeloma patients (ENDEAVOR). http://clinicaltrials.gov/show/NCT01568866 (accessed 2015 Jan 15).
38. Wang M, Martin T, Alsina M et al. Interim results from PX-171-006, a phase (Ph) II multicenter dose-expansion study of carfilzomib (CFZ), lenalidomide (LEN), and low-dose dexamethasone (loDex) in relapsed and/or refractory multiple myeloma (R/R MM). J Clin Oncol. 2011; 29(suppl):abstract 8025.
39. Jakubowiak AJ, Dytfeld D, Griffith KA et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood. 2012; 120:1801-9.
40. Palumbo A, Bringhen S, Villani O et al. Carfilzomib, cyclophosphamide and dexamethasone (CCd) for newly diagnosed multiple myeloma patients. https://ash.confex.com/ash/2012/webprogram/Paper46801.html (accessed 2014 Sep 18).
41. Kyprolis (carfilzomib) for injection prescribing information. South San Francisco, CA: Onyx Pharmaceuticals; 2012 Jul.
42. Gupta M, Pal RK, Tikoo D. Multiple myeloma: the disease and its treatment. Int J Basic Clin Pharmacol. 2013; 2:103-21.
43. Kropff M, Bisping G, Wenning D et al. Proteasome inhibition in multiple myeloma. Eur J Cancer. 2006; 42:1623-39.
44. Moreau P, Pylypenko H, Grosicki S et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011; 12:431-40.
45. Kortuem KM, Stewart AK. Carfilzomib. Blood. 2013; 121:893-7.
46. Siegel D, Martin T, Nooka A et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica. 2013; 98:1753-61.
47. Joseph J, Sacco JB, Fergus M et al. The average body surface area of adult cancer patients in the UK: a multicentre retrospective study. PLoS One. 2010; 5:e8933.
48. Red Book Online. Carfilzomib (Kyprolis). www.micromedexsolutions.com (accessed 2015 Jan 8).
49. Richardson PG, Sonneveld P, Schuster M et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final timeto-event results of the APEX trial. Blood. 2007; 110:3557-60.
50. Buda G, Ricci D, Huang CC et al. Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin. Ann Hematol. 2010; 89:1133-40.